Prevalence of Extended-spectrum beta-lactamases- producing Escherichia coli and Klebsiella pneumonia from patients attending Tripoli University Hospital, Tripoli, Libya
DOI:
https://doi.org/10.54361/ljmr.v17i2.08Keywords:
K. pneumoniae, E. coli, MDR, ESBLsAbstract
Prevalence of extended-spectrum β-lactamases (ESBLs)- producing E. coli and K. pneumoniae has been increased globally. The study aimed to detect the prevalence of ESBL-producing E. coli and K. pneumoniae isolated from clinical specimens in Tripoli university hospital (TUH) and to evaluate their antimicrobial resistance profile. We retrospectively reviewed the recorded cultures results in the microbiology laboratory, TUH during the first half of the year 2021. 77% of E. coli and 72.5% K. pneumonia were multidrug resistant. ESBL phenotype detected in 20% of K. pneumonia and 17.5% E. coli. ESBLs were isolated more frequently from the surgical ward (32.4%). ESBLs show high resistance to beta-lactam and other antibiotics including TMP/SMZ, and aminoglycosides. Our study showed a considerably high prevalence of ESBLs positive strains of E. coli and k. pneumoniae
Downloads
References
Pitout JD, Laupland KB. Extended-spectrum β-lactamase-producing Enterobacteriaceae: an emerging public-health concern. The Lancet Infect Dis 2008; 8(3):159-66.
World Health Organization (WHO) Scientific Working Group. Antimicrobial resistance. Bulletin of the World Health Organization. 1983;61(3):383.
European Centre for Disease Prevention and Control. Antimicrobial resistance surveillance in Europe 2015. Annual Report of the European Antimicrobial Resistance Surveillance Network (EARS-Net). Stockholm: ECDC; 2017.
Ghafourian S, Sadeghifard N, Soheili S, Sekawi Z. Extended spectrum beta-lactamases: definition, classification and epidemiology. Curr Issues Mol Biol. 2015 ;17(1):11-22.
Riccio ME, Verschuuren T, Conzelmann N, Martak D, Meunier A, Salamanca E, et al. Household acquisition and transmission of extended-spectrum β-lactamase (ESBL)-producing Enterobacteriaceae after hospital discharge of ESBL-positive index patients. Clin Microbiol Infect. 2021; 27(9):1322-29.
Duval A, Obadia T, Boëlle PY, Fleury E, Herrmann JL, Guillemot D, et al. Close proximity interactions support transmission of ESBL-K. pneumoniae but not ESBL-E. coli in healthcare settings. PLoS Comput Biol.2019;15(5).
Otter JA, Natale A, Batra R, Auguet OT, Dyakova E, Goldenberg SD, et al. Individual-and community-level risk factors for ESBL Enterobacteriaceae colonization identified by universal admission screening in London. Clin Microbiol Infect. 2019;25(10):1259-65.
Xercavins M, Jiménez E, Padilla E, Riera M, Freixas N, Boix-Palop L, et al. High clonal diversity of ESBL-producing Klebsiella pneumoniae isolates from clinical samples in a non-outbreak situation. A cohort study. Antimicrob Resist Infect Control. 2020; 1:1-9.
Mohammed I, Abass E. Phenotypic detection of Extended Spectrum β-Lactamases (ESBL) among gram negative uropathogens reveals highly susceptibility to imipenem. Pak J Med Sci. 2019;35(4):1104.
Zahar JR, Blot S, Nordmann P, Martischang R, Timsit JF, Harbarth S, et al. Screening for intestinal carriage of extended-spectrum Beta-lactamase–producing Enterobacteriaceae in critically ill patients: expected benefits and evidence-based controversies. Clin Infect Dis. 2019;68(12):2125-30.
Murphy D, Ricci A, Auce Z, Beechinor JG, Bergendahl H, Breathnach R, et al. Joint Scientific Opinion on measures to reduce the need to use antimicrobial agents in animal husbandry in the European Union, and the resulting impacts on food safety (RONAFA). EFSA Journal. 2017;15(1): EFSA J. 15:4666.
Falgenhauer L, Imirzalioglu C, Oppong K, Akenten CW, Hogan B, Krumkamp R, et al. Detection and characterization of ESBL-producing Escherichia coli from humans and poultry in Ghana. Front. Microbiol. 2019;9:3358.doi: 10.3389/fmicb.2018.03358.
Woerther PL, Andremont A, Kantele A. Travel-acquired ESBL-producing Enterobacteriaceae: impact of colonization at individual and community level. J Travel Med. 2017; 24(suppl_1): S29-34.
Arcilla MS, Van Hattem JM, Bootsma MC, van Genderen PJ, Goorhuis A, Grobusch MP, et al Prevalence and risk factors for carriage of ESBL-producing Enterobacteriaceae in a population of Dutch travellers: a cross-sectional study. Travel Med Infect Dis. 2020; 33:101547.
World Health Organization (WHO). Global Priority List of Antibiotic-Resistant Bacteria to Guide Research, Discovery, and Development of New Antibiotics. 2017.
Jansåker F, Boel JB, Thønnings S, Hertz FB, Hansen KH, Frimodt-Møller N, et al. Pivmecillinam compared to other antimicrobials for community-acquired urinary tract infections with E. coli ESBL-producing or not–a retrospective cohort study. Infect Drug Resist. 2019; 12:1691.
Hawkey PM, Warren RE, Livermore DM, McNulty CA, Enoch DA, Otter JA, et al. Treatment of infections caused by multidrug-resistant gram-negative bacteria: Report of the British society for antimicrobial chemotherapy/healthcare infection society/british infection association joint working party. J Antimicrob Chemother. 2018;73(suppl 3): 2-78.
Paterson DL, Isler B, Harris PN. PRO: Carbapenems should be used for ALL infections caused by ceftriaxone-resistant Enterobacterales. JACAntimicrob Resist. 2021 ;3(1):dlab013.
Giurazza R, Mazza MC, Andini R, Sansone P, Pace MC, Durante-Mangoni E. Emerging Treatment Options for Multi-Drug-Resistant Bacterial Infections. Life(Basel).2021;3;11(6):519.doi: 10.3390/life11060519. PMID: 34204961; PMCID: PMC8229628.
Zohar I, Schwartz O, Yossepowitch O, David SS, Maor Y. Aminoglycoside versus carbapenem or piperacillin/tazobactam treatment for bloodstream infections of urinary source caused by Gram-negative ESBL-producing Enterobacteriaceae. J Antimicrob Chemother. 2020;75(2):458-65.
Altayar MA, Thokar MA, Mohammad A. Extended-spectrum B-lactamase Producing E.coli in Clinical Isolates In Benghazi, Libya: Phenotypic Detection and Antimicrobial susceptibility Pattern. Med J Islam World Acad Sci. 2012;20(2):49–56.
Zorgani A, Almagatef A, Sufya N, Bashein A, Tubbal A. Detection of CTX-M-15 among uropathogenic Escherichia coli isolated from five major hospitals in Tripoli, Libya. Oman Med J. 2017;32(4):322.
Taher I,Shahlol1 AM, Abukhres OM. Prevalence and characterization of Extended-Spectrum β -Lactamase- producing enterobacteriaceae in Brack-Alshati, Fezzan, Libya. EC Microbiol. 2015;1(1):23–32.
Abujnah AA, Zorgani A, Sabri MA, El-Mohammady H, Khalek RA, Ghenghesh KS. Multidrug resistance and extended-spectrum β-lactamases genes among0 Escherichia coli from patients with urinary tract infections in Northwestern Libya. L J M. 2015;10(1).
Shallouf, M., Abrantes, P.M. Fielding, B and Africa CW. Colistin, Carbapenem and Cephalosporin-resistant Klebsiella pneumoniae reported from Misrata, Libya. S Afr J Infect Dis. 2017;32 (Supple:85).
Ahmad KM, Alamen AA, Shamsi SA, Elzen AA. Co-expression of Extended Spectrum βlactamase (ESBL) and AmpC β-lactamase among Pseudomonas aeruginosa clinical isolates in sebha medical center.J Appl Pure Sci Agric. 2019; 18(1):1-6.
Abdel-Moaty MM, Mohamed WS, Abdel-All SM, El-Hendawy HH. Prevalence and molecular epidemiology of extended spectrum β-lactamase producing Escherichia coli from hospital and community settings in Egypt. J App Pharm Sci, 2016; 6 (01): 042- 047.
Fam NS, Defasque S, Bert F. Faecal carriage of extended-spectrum β -lactamase (ESBL)-producing enterobacteria in liver disease patients from two hospitals in Egypt and France : a comparative epidemiological study.Infect Epidemiol Microbiol 2015; 143:1247–1255.
Khater ES, Sherif HW. Rapid Detection of Extended Spectrum Β-lactamase (ESBL) Producing Strain of Escherichia coli in Urinary Tract Infections Patients in Benha University Hospital, Egypt. Br Microbiol Res J. 2014;4(4):443–53.
Noha AH, Ahmed SK, Eman MF, Adel MH, Medhat AF. Molecular characterization of extended-spectrum β lactamase-producing E.colirecovered from community- acquired urinary tract infections in Upper Egypt. Sci Rep. 2020;10:2772.
Moges F, Eshetie S, Abebe W, Mekonnen F, Dagnew M, Endale A, etal. High prevalence of extended-spectrum beta-lactamase-producing Gram-negative pathogens from patients attending Felege Hiwot Comprehensive Specialized Hospital, Bahir Dar, Amhara region. PloS one. 2019;14(4): 1-13.
Moremi N, Silago V, Mselewa EG, Chifwaguzi AP, Mirambo MM, Mushi MF, et al. Extended-spectrum β-lactamase blaCTX-M-1 group in gram-negative bacteria colonizing patients admitted at Mazimbu hospital and Morogoro Regional hospital in Morogoro, Tanzania. BMC Res Notes. 2021;14(1):1-7.
Marando R, Seni J, Mirambo MM, Falgenhauer L, Moremi N, Mushi MF, et al. Predictors of the extended-spectrum-beta lactamases producing Enterobacteriaceae neonatal sepsis at a tertiary hospital, Tanzania. Int J Med Microbiol. 2018;308(7):803-11.
El-Kersh TA, Marie MA, Al-Sheikh YA, Al-Kahtani SA. Prevalence and risk factors of community-acquired urinary tract infections due to ESBL-producing Gram negative bacteria in an Armed Forces Hospital in Sothern Saudi Arabia. Glo. Adv. Res. J. Med. Med. Sci. 2015;4(7):321-30.
Aldrazi FA, Rabaan AA, Alsuliman SA, Aldrazi HA, Alabdalslam MJ, Alsadiq SA, et al. ESBL expression and antibiotic resistance patterns in a hospital in Saudi Arabia: Do healthcare staff have the whole picture?J Infect Public Health. 2020;13(5):759-66.
Alyamani EJ, Khiyami AM, Booq RY, Majrashi MA, Bahwerth FS, Rechkina E. The occurrence of ESBL-producing Escherichia coli carrying aminoglycoside resistance genes in urinary tract infections in Saudi Arabia. Ann Clin Microbiol Antimicrob. 2017;16(1):1-3.
Taha SA, Omar HH. Characterization of plasmid-mediated qnrA and qnrB genes among Enterobacteriaceae strains: quinolone resistance and ESBL production in Ismailia, Egypt. Egypt J Med Hum Genet 2019;20(1):1-7.
Mohamed ES, Khairy RM, Abdelrahim SS. Prevalence and molecular characteristics of ESBL and AmpC β-lactamase producing Enterobacteriaceae strains isolated from UTIs in Egypt. Antimicrob Resist Infect Control 2020;9(1):1-9.
Clinical and Laboratory Standards Institute. CLSI. Performance Standards for Antimicrobial Susceptibility Testing. CLSI supplement M100. 32nd ed. 2022.
Osthoff M, McGuinness SL, Wagen AZ, Eisen DP. Urinary tract infections due to extended-spectrum beta-lactamase-producing Gram-negative bacteria: identification of risk factors and outcome predictors in an Austral.
Downloads
Published
Issue
Section
License
Copyright (c) 2023 Dalal A. Thwood, Zaynab A. Elgadiym, Maren F. Hnaya, Amina Abosedra (Author)
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Open Access Policy
Libyan journal of medical Research (LJMR).is an open journal, therefore there are no fees required for downloading any publication from the journal website by authors, readers, and institution.
The journal applies the license of CC BY (a Creative Commons Attribution 4.0 International license). This license allows authors to keep ownership f the copyright of their papers. But this license permits any user to download , print out, extract, reuse, archive, and distribute the article, so long as appropriate credit is given to the authors and the source of the work.
The license ensures that the article will be available as widely as possible and that the article can be included in any scientific archive.
Editorial Policy
The publication of an article in a peer reviewed journal is an essential model for Libyan journal of medical Research (LJMR). It is necessary to agree upon standards of expected ethical behavior for all parties involved in the act of publishing: the author, the journal editorial, the peer reviewer and the publisher.
Any manuscript or substantial parts of it, submitted to the journal must not be under consideration by any other journal. In general, the manuscript should not have already been published in any journal or other citable form, although it may have been deposited on a preprint server. Authors are required to ensure that no material submitted as part of a manuscript infringes existing copyrights, or the rights of a third party.
Authorship Policy
The manuscript authorship should be limited to those who have made a significant contribution and intellectual input to the research submitted to the journal, including design, performance, interpretation of the reported study, and writing the manuscript. All those who have made significant contributions should be listed as co-authors.
Others who have participated in certain substantive aspects of the manuscript but without intellectual input should only be recognized in the acknowledgements section of the manuscript. Also, one of the authors should be selected as the corresponding author to communicate with the journal and approve the final version of the manuscript for publication in the LJMR.
Peer-review Policy
- All the manuscripts submitted to LJMR will be subjected to the double-blinded peer-review process;
- The manuscript will be reviewed by two suitable experts in the respective subject area.
- Reports of all the reviewers will be considered while deciding on acceptance/revision or rejection of a manuscript.
- Editor-In-Chief will make the final decision, based on the reviewer’s comments.
- Editor-In-Chief can ask one or more advisory board members for their suggestions upon a manuscript, before making the final decision.
- Associate editor and review editors provide administrative support to maintain the integrity of the peer-review process.
- In case, authors challenge the editor’s negative decision with suitable arguments, the manuscript can be sent to one more reviewer and the final decision will be made based upon his recommendations.
